Clinical trials located in


Ostend city is located in Belgium. Currently, 6 clinical trials are being conducted in this city.

Ostend, a vibrant city on the Belgian coast, is renowned for its extensive beaches and the Mercator, a retired sailing ship now a museum. It was the birthplace of famous painter James Ensor, whose works are displayed in the Mu.ZEE art museum. The city also boasts the Atlantic Wall Open Air Museum, showcasing remnants of WWII fortifications. Ostend’s rich history is intertwined with maritime and cultural heritage, making it a unique blend of past and present.

  • CT-EU-00067491

    Testing personalized treatments for advanced prostate cancer

    ProBio is a worldwide study for patients with advanced prostate cancer. It will look at whether new treatments can help patients based on their unique cancer characteristics. Patients are allocated in two groups: one will receive usual care following local guidelines (control group). The other group will be given treatments designed specifically for their type of cancer. These treatments will be chosen based on their cancer’s unique characteristics – what is called ‘biomarker signatures’. Depending on how well they respond to the treatment, patients may be moved to different treatments. Each treatment will be compared to standard care for effectiveness. The researchers will decide if treatments are effective, should continue, or should be stopped. New types and combinations of treatments can be included in the future. The study will use well-established standards to assess cancer improvement. Quality of life and costs of the treatment will also be evaluated. Side effects and responses to treatment at 6 months will also be recorded.

    • Abiraterone
    • Cabazitaxel
    • Radium Chloride Ra-223
    • enzalutamide
    • Apalutamide
    • Niraparib
    • Darolutamide
    • Capivasertib
    • Prednisone
    • Carboplatin
    • Docetaxel
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Testing birtamimab for safety and effectiveness in patients with severe AL Amyloidosis

    This medical study aims to investigate a drug called birtamimab to understand if it effectiveness and is safe for people in the advanced stage (Mayo Stage IV) of a disease called AL Amyloidosis. In this study, scientists are comparing the outcomes of two groups of people: one group receiving birtamimab in addition to standard-of-care chemotherapy, and another group receiving a neutral drug (placebo) along with standard-of-care chemotherapy. The goal is to assess whether the group receiving birtamimab has better results or outcomes compared to the group receiving the placebo. Patients will be chosen randomly to either receive birtamimab or placebo. The study includes an Open-label Extension (OLE) Phase, which allows participants who complete the initial trial phase to continue receiving birtamimab.

    • Birtamimab
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine

See more clinical trials in other cities in Belgium: